Janus kinase inhibitors role in bone remodeling

被引:17
作者
Maruotti, Nicola [1 ]
Corrado, Addolorata [1 ]
Rotondo, Cinzia [1 ]
Cantatore, Francesco Paolo [1 ]
机构
[1] Univ Foggia, Med Sch, Dept Med & Surg Sci, Rheumatol Clin, Foggia, Italy
关键词
bone; cytokine; osteoblast; osteoclast; REGULATORY T-CELLS; KAPPA-B LIGAND; OSTEOCLAST DIFFERENTIATION; RECEPTOR ACTIVATOR; SIGNALING PATHWAYS; JAK INHIBITION; NUCLEAR-FACTOR; ARTHRITIS; PROTEIN; RANKL;
D O I
10.1002/jcp.29149
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Janus kinases (JAKs) play a pleiotropic role in several important physiological processes, such as cell maturation, cell proliferation, and cell death, via providing transmission signals from several molecules, such as cytokines, interferons, hormones, and growth factors, to the nucleus. Bone physiology and remodeling are markedly influenced by proinflammatory cytokines. Among them, interleukin-1 (IL-1) and IL-6 are considered potent stimulator of bone resorption. Several cytokine receptors, such as IL-6 receptors, are characterized by tyrosine kinases of the JAK family associated with their intracellular domains. There is an emerging interest in the effects of JAKs inhibition on the cells involved in bone remodeling. JAK inhibitors represent a new class of molecules involved in the therapy of numerous immune-mediated inflammatory diseases. In this review, we want to focus on the role of JAKs inhibitors on bone remodeling and on RANKL-RANK-OPG signal and inflammatory cytokines which are involved in the regulation of bone cells, such as osteoblasts and osteoclasts.
引用
收藏
页码:1915 / 1920
页数:6
相关论文
共 55 条
[1]   The tyrosine kinase inhibitor tyrphostin AG126 reduces activation of inflammatory cells and increases Foxp3+ regulatory T cells during pathogenesis of rheumatoid arthritis [J].
Ahmad, Sheikh Fayaz ;
Ansari, Mushtaq Ahmad ;
Nadeem, Ahmed ;
Zoheir, Khairy M. A. ;
Bakheet, Saleh A. ;
Al-Shabanah, Othman A. ;
Al Rikabi, Ammar Cherkess ;
Attia, Sabry M. .
MOLECULAR IMMUNOLOGY, 2016, 78 :65-78
[2]   FHL2 inhibits the activated osteoclast in a TRAF6-dependent manner [J].
Bai, ST ;
Kitaura, H ;
Zhao, HB ;
Chen, J ;
Müller, JM ;
Schüle, R ;
Darnay, B ;
Novack, DV ;
Ross, FP ;
Teitelbaum, SL .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (10) :2742-2751
[3]   Bone remodelling: locus minori or unappreciated potential of tofacitinib? [J].
Bokarewa, Maria I. ;
Erlandsson, Malin C. .
RHEUMATOLOGY, 2018, 57 (08) :1318-1320
[4]   The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis [J].
Boyle, D. L. ;
Soma, K. ;
Hodge, J. ;
Kavanaugh, A. ;
Mandel, D. ;
Mease, P. ;
Shurmur, R. ;
Singhal, A. K. ;
Wei, N. ;
Rosengren, S. ;
Kaplan, I. ;
Krishnaswami, S. ;
Luo, Z. ;
Bradley, J. ;
Firestein, G. S. .
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (06) :1311-1316
[5]   Osteoclast differentiation and activation [J].
Boyle, WJ ;
Simonet, WS ;
Lacey, DL .
NATURE, 2003, 423 (6937) :337-342
[6]   Regulatory effect of calcineurin inhibitor, tacrolimus, on IL-6/sIL-6R-mediated RANKL expression through JAK2-STAT3-SOCS3 signaling pathway in fibroblast-like synoviocytes [J].
Choe, Jung-Yoon ;
Park, Ki-Yeun ;
Park, Sung-Hoon ;
Lee, Sang-Il ;
Kim, Seong-Kyu .
ARTHRITIS RESEARCH & THERAPY, 2013, 15 (01)
[7]   SOCS regulation of the JAK/STAT signalling pathway [J].
Croker, Ben A. ;
Kiu, Hiu ;
Nicholson, Sandra E. .
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2008, 19 (04) :414-422
[8]   JNK1 modulates osteoclastogenesis through both c-Jun phosphorylation-dependent and -independent mechanisms [J].
David, JP ;
Sabapathy, K ;
Hoffmann, O ;
Idarraga, MH ;
Wagner, EF .
JOURNAL OF CELL SCIENCE, 2002, 115 (22) :4317-4325
[9]   c-Fms and the αvβ3 integrin collaborate during osteoclast differentiation [J].
Faccio, R ;
Takeshita, S ;
Zallone, A ;
Ross, FP ;
Teitelbaum, SL .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (05) :749-758
[10]   Murine osteoclast formation and function: Differential regulation by humoral agents [J].
Fuller, K ;
Kirstein, B ;
Chambers, TJ .
ENDOCRINOLOGY, 2006, 147 (04) :1979-1985